nerve cells

Implantable Tibial Nerve Stimulation added as Treatment Option within AUA/SUFU 2024 OAB Guideline

Valencia Technologies is pleased to announce that implantable tibial nerve stimulation (ITNS) has been acknowledged as a minimally invasive OAB treatment option in the recently updated American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) clinical practice Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder (2024). The eCoin® ITNS device is the only fully implantable FDA PMA approved device for treating urge urinary incontinence (UUI), the primary symptom of OAB. The eCoin ITNS system commercialized in March 2022 has now been used to treat over 1,100 patients in the United States. This highlights the significant need for evolutionary treatment options to address the growing burden of a largely underserved OAB population. Read more.

Source: PRNewswire, May 2, 2024

tibial nerve

AUA/SUFU Guideline on the Treatment of Overactive Bladder Allows Access to Revi™ System Earlier in Treatment Journey

BlueWind Medical, Ltd., a pioneer in implantable Tibial NeuroModulation (iTNM) and the developer of ReviTM, a patient-centric solution for urge urinary incontinence (UUI), announced today that the Revi System, a minimally invasive therapy, is now included in the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) clinical practice guideline on the diagnosis and treatment of idiopathic overactive bladder (OAB). The revised guidelines are a major affirmation of the importance of Revi as a therapy for patients with UUI. First, the guidelines were updated to include iTNM as an acceptable minimally invasive therapy.  In addition, the revised guidelines shift away from traditional step therapy approaches, allowing physicians and patients to bypass behavioral and pharmacotherapy before considering minimally invasive therapies, including Revi.  Read more.

Source: PRNewswire, April 29, 2024

coffee

How Switching to Decaf Could Save NHS £85m a Year

In the first-of-its-kind trial, care home residents were offered decaffeinated hot drinks in a bid to reduce falls experienced rushing to the toilet.  Conducted across eight residential Stow Healthcare homes over six months, the simple switch resulted in a 35% reduction in toileting-related falls.  If scaled across the sector, the results, a study suggested, would mean thousands of falls prevented and NHS savings of up to £85 million per year.  This is according to a joint report published today by Care England, Stow Healthcare and University Hospitals of Leicester NHS Trust (UHL).  The trial followed a similar initiative by UHL in 2021. Noticing that many hospital patients were falling on the way to the toilet, Continence Nurse Specialist Sarah Coombes suggested switching to decaffeinated drinks to reduce bladder and bowel urgency in those with an overactive bladder or incontinence. Within three months, toileting-related falls in the hospital were down by 30%.  Read more.

Source: Care Home Professional, April 24, 2024

nurse and patient

Published Data Demonstrate Excellent Safety and Efficacy and Reinforce Patient Satisfaction with Revi™ System in the Treatment of Urge Urinary Incontinence

BlueWind Medical, Ltd., a pioneer in implantable Tibial NeuroModulation (iTNM) and the developer of ReviTM, a patient-centric solution for urge urinary incontinence (UUI), today announced that the peer-reviewed results from the OASIS pivotal trial were published in the Journal of Neurourology and Urodynamics (NAU). OASIS, a prospective, multicenter, single-arm, open-label clinical study of 151 women, was designed to demonstrate the safety and efficacy of Revi in reducing symptoms of overactive bladder (OAB).  The trial results demonstrate a statistically significant improvement with a 78.4% clinical success rate as defined by at least a 50% reduction in UUI at 12 months in the intention to treat (ITT) analysis (p<.0001). Read more.

Source: PRNewswire, April 23, 2024

measuring tape obesity

Abdominal Obesity Might Predict Risk of Fecal Incontinence

Fecal incontinence (FI), or involuntary loss of bowel control, significantly impacts quality of life and mental health for millions of adults in the U.S. Obesity is thought to affect bowel function, but the relationship between its standardized measure, body mass index (BMI), and FI remains unclear. Examining better markers of obesity that include body composition and fat distribution, rather than BMI alone, could help clarify the effect of obesity on FI. Read more.

Source: Medical Xpress, April 22, 2024

Urinary Implant Helps Patients With Incontinence Track Bladder Fullness

It’s hard for some folks who suffer illness-related urinary incontinence to judge whether they’ll be able to hold it until they get home, or if they should rush to a bathroom now.  There might soon be a new app for that.  A newly developed soft, flexible, battery-free implant attaches to the bladder wall and senses the organ filling with urine, according to researchers at Northwestern University in Chicago.  The implant wirelessly transmits data to a smartphone app, so patients can track their bladder fullness in real time, researchers said. Read more.

Source: UPI, March 26, 2024

Bacteria

How Urobiome Composition Impacts Urinary Incontinence

A urobiome community type with fewer Lactobacilli and more diverse bacteria is associated with more severe urinary incontinence (UI) episodes vs a type with high predominance of a single genus, Lactobacillus, according to a recent study published in the American Journal of Obstetrics & Gynecology. Bacteria has been categorized into various niches, including the bladder niche and adjacent vaginal niche in women. Sequencing methods allow for urothelial and squamous intracellular bacteria to be identified. These bacteria may serve as reservoirs for chronic conditions such as urinary tract infection (UTI). Read more.

Source: Contemporary OB/GYN, March 19, 2024

clinical medical

Affluent Medical Touts First Implant of Artificial Urinary Sphincter

Affluent Medical today announced the successful first-in-human implant of its minimally invasive urinary incontinence treatment device.  Dr. Roman Zachoval completed the first implant of Artus, an artificial urinary sphincter. Zachoval, head of urology at Thomayer University Hospital in Prague, implanted Artus in a 68-year-old male patient with severe urinary incontinence. Read more.

Source: Mass Device, March 12, 2024

VCU Health Leads Clinical Trial For New treatment To Help People With Bowel Control Problems

A research team at VCU Health is leading a clinical trial to assess a novel treatment for fecal incontinence or sudden loss of control over bowel movements. The therapy involves implanting a bioengineered sphincter derived from the patient’s native cells to help them regain control of their bowels.  The implantation surgery for the clinical trial is being led by Jaime Bohl, M.D., an associate professor in the Department of Surgery and chief of the Division of Colon and Rectal Surgery at Virginia Commonwealth University’s School of Medicine. Read more.

Source: VCU Health, February 28, 2024

nerve cells

Amber Therapeutics Announces Positive Preliminary Results From Its First-In-Human Investigation of Amber-UI, Its New Adaptive Implanted Pudendal Neuromodulation System for Urinary Incontinence

Amber Therapeutics (‘Amber’ or the ‘Company’), an innovative medical technology company developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system, announces the presentation of the first data from its AURA-2 (Augmenting Urinary Reflex Activity) first-in-human study evaluating Amber-UI.  Amber-UI is the first fully implantable closed-loop bioelectrical therapy in clinical development for urinary incontinence (UI), which is made possible by being able to access and target the pudendal nerve – the nerve that directly controls continence – through a novel, minimally invasive surgical procedure. Read more.

Source: WWLP.com, February 27, 2024